Ine Lentacker

Dr. Lentacker is a pharmacist and obtained her PhD in Pharmaceutical sciences at Ghent University in 2009. Currently, she is a group leader in the Ghent Research Group on Nanomedicines where she leads a research team at the interface of material design, drug delivery and immunology with a major focus on mRNA vaccines and adjuvant formulation. A phase I clinical trial for the adjuvanted mRNA vaccine platform “Galsomes” is currently being set-up in cancer patients.